Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. / Ahrén, Bo; Simonsson, Erik; Larsson, Hillevi; Landin-Olsson, Mona; Torgeirsson, Hlin; Jansson, Per-Anders; Sandqvist, Madeléne; Båvenholm, Peter; Efendic, Suad; Eriksson, Jan W; Dickinson, Sheila; Holmes, David.

I: Diabetes Care, Vol. 25, Nr. 5, 2002, s. 869-875.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Ahrén, B, Simonsson, E, Larsson, H, Landin-Olsson, M, Torgeirsson, H, Jansson, P-A, Sandqvist, M, Båvenholm, P, Efendic, S, Eriksson, JW, Dickinson, S & Holmes, D 2002, 'Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.', Diabetes Care, vol. 25, nr. 5, s. 869-875. https://doi.org/10.2337/diacare.25.5.869

APA

CBE

Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. 2002. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 25(5):869-875. https://doi.org/10.2337/diacare.25.5.869

MLA

Vancouver

Author

Ahrén, Bo ; Simonsson, Erik ; Larsson, Hillevi ; Landin-Olsson, Mona ; Torgeirsson, Hlin ; Jansson, Per-Anders ; Sandqvist, Madeléne ; Båvenholm, Peter ; Efendic, Suad ; Eriksson, Jan W ; Dickinson, Sheila ; Holmes, David. / Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. I: Diabetes Care. 2002 ; Vol. 25, Nr. 5. s. 869-875.

RIS

TY - JOUR

T1 - Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

AU - Ahrén, Bo

AU - Simonsson, Erik

AU - Larsson, Hillevi

AU - Landin-Olsson, Mona

AU - Torgeirsson, Hlin

AU - Jansson, Per-Anders

AU - Sandqvist, Madeléne

AU - Båvenholm, Peter

AU - Efendic, Suad

AU - Eriksson, Jan W

AU - Dickinson, Sheila

AU - Holmes, David

PY - 2002

Y1 - 2002

N2 - OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the drawback of the short half-life of GLP-1, inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase IV (DPP IV) have been examined. Such inhibitors improve glucose tolerance in insulin-resistant rats and mice. In this study, we examined the 4-week effect of 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP DPP728), a selective, orally active inhibitor of DPP IV, in subjects with diet-controlled type 2 diabetes in a placebo-controlled double-blind multicenter study. RESEARCH DESIGN AND METHODS: A total of 93 patients (61 men and 32 women), aged 64 +/- 9 years (means +/- SD) and with BMI 27.3 +/- 2.7 kg/m(2), entered the study. Fasting blood glucose was 8.5 +/- 1.5 mmol/l, and HbA(1c) was 7.4 +/- 0.7%. Before and after treatment with NVP DPP728 at 100 mg x 3 (n = 31) or 150 mg x 5 (n = 32) or placebo (n = 30), subjects underwent a 24-h study with standardized meals (total 2,000 kcal). RESULTS: Compared with placebo, NVP DPP728 at 100 mg t.i.d. reduced fasting glucose by 1.0 mmol/l (mean), prandial glucose excursions by 1.2 mmol/l, and mean 24-h glucose levels by 1.0 mmol/l (all P < 0.001). Similar reductions were seen in the 150-mg b.i.d. treatment group. Mean 24-h insulin was reduced by 26 pmol/l in both groups (P = 0.017 and P = 0.023). Although not an efficacy parameter foreseen in the study protocol, HbA(1c) was reduced to 6.9 +/- 0.7% in the combined active treatment groups (P < 0.001). Laboratory safety and tolerability was good in all groups. CONCLUSIONS: We conclude that inhibition of DPP IV is a feasible approach to the treatment of type 2 diabetes in the early stage of the disease.

AB - OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the drawback of the short half-life of GLP-1, inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase IV (DPP IV) have been examined. Such inhibitors improve glucose tolerance in insulin-resistant rats and mice. In this study, we examined the 4-week effect of 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP DPP728), a selective, orally active inhibitor of DPP IV, in subjects with diet-controlled type 2 diabetes in a placebo-controlled double-blind multicenter study. RESEARCH DESIGN AND METHODS: A total of 93 patients (61 men and 32 women), aged 64 +/- 9 years (means +/- SD) and with BMI 27.3 +/- 2.7 kg/m(2), entered the study. Fasting blood glucose was 8.5 +/- 1.5 mmol/l, and HbA(1c) was 7.4 +/- 0.7%. Before and after treatment with NVP DPP728 at 100 mg x 3 (n = 31) or 150 mg x 5 (n = 32) or placebo (n = 30), subjects underwent a 24-h study with standardized meals (total 2,000 kcal). RESULTS: Compared with placebo, NVP DPP728 at 100 mg t.i.d. reduced fasting glucose by 1.0 mmol/l (mean), prandial glucose excursions by 1.2 mmol/l, and mean 24-h glucose levels by 1.0 mmol/l (all P < 0.001). Similar reductions were seen in the 150-mg b.i.d. treatment group. Mean 24-h insulin was reduced by 26 pmol/l in both groups (P = 0.017 and P = 0.023). Although not an efficacy parameter foreseen in the study protocol, HbA(1c) was reduced to 6.9 +/- 0.7% in the combined active treatment groups (P < 0.001). Laboratory safety and tolerability was good in all groups. CONCLUSIONS: We conclude that inhibition of DPP IV is a feasible approach to the treatment of type 2 diabetes in the early stage of the disease.

U2 - 10.2337/diacare.25.5.869

DO - 10.2337/diacare.25.5.869

M3 - Article

VL - 25

SP - 869

EP - 875

JO - Diabetes Reviews

JF - Diabetes Reviews

SN - 1935-5548

IS - 5

ER -